This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Register to Win a Pair of Tickets to see SO TRUE LIVE TOUR WITH CALEB HEARON Register to Win a Pair of Tickets to see SO TRUE LIVE TOUR WITH CALEB HEARON Music and the Mirror (& Mobility Aids): ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

Several DPP-4 inhibitors are in clinical development; these are orally active and increase levels of active GLP-1, which in turn increases insulin secretion and reduces glucagon secretion and ...

Use of GLP-1RAs vs DPP-4 inhibitors was not associated with an increased risk for thyroid cancer. No evidence suggests increased thyroid cancer risk associated with use of glucagon-like peptide-1 ...

Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i) have demonstrated ...

A recent study conducted across public hospitals in Hong Kong highlighted the superiority of sodium-glucose cotransporter 2 (SGLT2) inhibitors over dipeptidyl peptidase-4 (DPP-4) inhibitors in ...

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Many rewards credit cards offer cash back, and you may ...

those using a DPP-IV inhibitor. Women may have a lower risk ... the C-cell effects of GLP-1 receptor agonists in rats and mice do not appear to be replicated in primates. However, randomized ...

January 29, 2025 Introducing "Study Break" January 29, 2025 • Welcome to How To Do Everything's "study break". This Friday at 12 PM CT, we will drop a Zoom link in this Google document. The ...